U.S. Markets close in 2 hrs 10 mins
  • S&P 500

    3,620.96
    -19.51 (-0.54%)
     
  • Dow 30

    28,983.31
    -242.30 (-0.83%)
     
  • Nasdaq

    10,701.84
    -35.67 (-0.33%)
     
  • Russell 2000

    1,695.63
    +20.69 (+1.24%)
     
  • Crude Oil

    79.97
    -1.26 (-1.55%)
     
  • Gold

    1,670.30
    +1.70 (+0.10%)
     
  • Silver

    19.04
    +0.33 (+1.75%)
     
  • EUR/USD

    0.9792
    -0.0027 (-0.2742%)
     
  • 10-Yr Bond

    3.7480
    +0.0010 (+0.03%)
     
  • Vix

    30.28
    -1.56 (-4.90%)
     
  • GBP/USD

    1.1142
    +0.0019 (+0.1671%)
     
  • USD/JPY

    144.7420
    +0.2990 (+0.2070%)
     
  • BTC-USD

    19,658.24
    +223.92 (+1.15%)
     
  • CMC Crypto 200

    448.83
    +5.40 (+1.22%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

Spero Therapeutics Shares Jump After Upbeat FDA Feedback For Tebipenem HBr Program

·1 min read
  • Spero Therapeutics Inc (NASDAQ: SPROreceived minutes from a recent Type A meeting with the FDA, discussing steps required to resubmit the marketing application for tebipenem HBr for complicated urinary tract infection (cUTI).

  • During the Type A meeting, the FDA indicated that positive results from an additional Phase 3 trial supported by confirmatory nonclinical efficacy evidence could be sufficient to support the approval of tebipenem HBr for cUTI, including pyelonephritis for a limited use indication.

  • Spero and the FDA also aligned the key components of the proposed pivotal Phase 3 trial design, which may be the subject of a Special Protocol Assessment request, to be confirmed once the clinical protocol is finalized.

  • Spero received a Complete Response Letter from the FDA in June 2022, citing data from Spero's initial Phase 3 cUTI clinical trial, ADAPT-PO, that were insufficient to support approval.

  • Also read: FDA Identifies Review Issues For Spero's Tebipenem Application, Shares Plunge.

  • Spero plans to advance tebipenem HBr's clinical development and potential commercialization through external partnership.

  • If approved, tebipenem HBr would be the first oral carbapenem antibiotic to receive FDA approval.

  • Price Action: SPRO shares are up 10.50% at $0.80 on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.